Bonti
4921 Birch Street
Suite 120
Newport Beach
California
92660
United States
Fax: 949-266-5572
Website: http://bonti.com/
About Bonti
Bonti is a rapidly emerging biotech company focused on developing novel treatments, driven by our unique neurotoxin platform, for aesthetic and therapeutic indications for conditions with unmet needs.YEAR FOUNDED:
June 13, 2015
LEADERSHIP:
Co-Founder & CEO: Fauad Hasan, MS, MBA
Co-Founder & COO: Wajdie Ahmad, MBA
Co-Founder & Executive VP, Drug Development: Mike Jarpe, Ph.D.
Co-Founder & Director: David Ramsay
Director: Dennis Huang
Director: Tom Albright
CAREER:
Please click here for Bonti's job opportunities.
15 articles about Bonti
-
Dublin-based Allergan is acquiring Newport Beach, California-based Bonti with an upfront payment of $195 million.
-
Bonti Announces Presentation Featuring EB-001A at Masters of Aesthetics Symposium
8/23/2018
Dr. Jean Carruthers to Highlight Key Aesthetic Clinical Study Results for This Novel Neurotoxin with a Unique Clinical Profile
-
Bonti Announces Successful Completion of Phase 2a Scar Reduction Clinical Study
8/2/2018
Bonti today announced the topline results of its SHINE-1 Phase 2a clinical trial.
-
Bonti Announces Start of LANTERN-2 Phase 2 Clinical Trial Evaluating EB-001T in Treating Focal Muscle Pain
5/9/2018
Program aimed at treating focal muscle pain and reducing use of rescue medications, including opioids.
-
Bonti Appoints Dr. Jacob Chacko to Board of Directors
2/12/2018
Bonti today announced the appointment of Dr. Jacob Chacko to its Board of Directors, effective immediately.
-
Bonti Announces Dosing of the First Patient in the SHINE-1 Phase II Clinical Study Evaluating EB-001 for Scar Reduction
2/8/2018
Bonti announced the initiation of the SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin.
-
Bonti Announces Close of $15.5 Million Series C Funding and Appointment of David Ramsay as Chief Financial Officer
1/23/2018
Bonti announced it successfully closed a $15.5 million Series C financing, bringing the cumulative investment in the Company to over $36 million.
-
Bonti Announces Hot Topics Presentation Featuring EB-001 At Plastic Surgery The Meeting
10/9/2017
-
Bonti Announces Presentation Of EB-001 Clinical Study Results At American Society for Dermatologic Surgery Annual Meeting
9/13/2017
-
Bonti Announces Start Of LANTERN-1 Phase II Clinical Study Evaluating EB-001 In Reducing Musculoskeletal Pain
8/23/2017
-
Bonti Announces Topline Results Of EB-001 Phase IIA Clinical Study In Glabellar Lines
8/10/2017
-
Bonti Announces Poster Presentation On EB-001 Pharmacological Profile At Abdominal Wall Reconstruction Conference
6/6/2017
-
Bonti Announces Hot Topics Presentation Of Phase IIa Interim Clinical Data At The Aesthetic Meeting 2017
5/3/2017
-
Bonti Announces Inaugural Presentation Of Phase IIa Clinical Data For Its Lead Product EB-001
4/27/2017
-
Bonti Raises $11.7 Million In An Oversubscribed Series B Financing To Advance Development Of Lead Product EB-001
4/18/2017